Agios Pharmaceuticals (AGIO) Stock Analysis & AI Equity Report
Agios Pharmaceuticals (AGIO) overview
Agios Pharmaceuticals (AGIO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 54.0m and operating profit of USD -472m; the year-end share price was 27.22 USD and market capitalisation was USD 1,591m. Agios Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Agios Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Agios Pharmaceuticals
Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare disease medicines, with a foundation in hematology. Its approved medicine mitapivat is marketed as AQVESME and PYRUKYND for specified forms of thalassemia and pyruvate kinase deficiency. The company is also developing medicines for conditions including myelodysplastic syndromes, sickle cell disease, phenylketonuria and polycythemia vera.
Generate the Agios Pharmaceuticals report
Agios Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Agios Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Agios Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.